Child pages
  • Multi-center breast DCE-MRI data and segmentations from patients in the I-SPY 1/ACRIN 6657 trials (ISPY1)

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Cleaned up tables. Minor text changes

Summary

...

BACKGROUND

ACRIN 6657 was designed as a prospective study to test MRI for ability to predict response to treatment and risk-of-recurrence in patients with stage 2 or 3 breast cancer receiving neoadjuvant chemotherapy (NACT). ACRIN 6657 was conducted as a companion study to CALGB 150007, a correlative science study evaluating tissue-based biomarkers in the setting of neoadjuvant treatment of breast cancer. Collectively, CALGB 150007 and ACRIN 6657 formed the basis of the multicenter Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis (I-SPY TRIAL) breast cancer trial, a study of imaging and tissue-based biomarkers for predicting response and survivalAdd protocol references for all three studies.
Participant Eligibility and Enrollment: Criteria for inclusion were patients enrolling on CALGB 150007 with T3 tumors measuring at least 3 cm in diameter by clinical exam or imaging and receiving neoadjuvant chemotherapy with an  anthracycline-cyclophosphamide regimen alone or followed by a taxane. Pregnant patients and those with ferromagnetic prostheses were excluded from the study. The study was open to enrollment from May 2002 to March 2006. 237 patients were enrolled, of which 230 met eligibility criteria.

...

Info

This is a limited access data set. To request access, please contact (ACRIN Contact) help@cancerimagingarchive.net. If access is granted you  will you will be able to view and download these images on The Cancer Imaging Archive (TCIA) by logging in and selecting the I-SPY1 collection. This data set will be made publicly available on or before July 1, 2016.

...

If you are unsure how to download this Collection please view our quick guide on Searching by Collection or refer to our The Cancer Imaging Archive User's Guide for more detailed instructions on using the site.

Shared Lists

...

  • Coming soon

...

: See descriptions below under "Curated Data Sets"   [   NEED TO MAKE THESE LINKS TO DOWNLOAD SETS ]

  • Longest Diameter (LD) dataset
  • Good SER Functional Tumor Volume (FTV)
  • ACRIN 6657 Analysis Set

Imaging Data Transfer Process

...

Studies with MRI measured longest diameter
839 MR studies have LD reported in the I-SPY 1 clinical database
834 MR studies (219 subjects) in UCSF image database with LD

5 studies that have LD measurement are missing from the UCSF and ACRIN TRIAD image data collections:

 

 

1071, T0
1138, T0

1101, T2
1040, T3

1187, T3

...

708 MR studies (208 subjects) in UCSF image database

 

7 studies in Level 2a that do NOT have LD measures:

 

ID 1059, T3
ID 1079 * , T1
ID 1104, T3

ID 1192, T1
ID 1212, T3

ID 1215, T0
ID 1238, T1

   
  • Patient 1079 does not appear in the Feb. 2, 2011 I-SPY FINAL LOCKED clinical data set. So no clinical data is available.

...

...

 

Level 2b: SER Volume Dataset submitted to ACRIN in 2008

707 MR studies (207 subjects) in UCSF image database
Differences between Levels 2a and 2b:

15 exams accepted for SER analysis since 2008 (in Level 2a but not in 2b)

 

 

ID 1005, T2
ID 1043, T1
ID 1046, T3
ID 1057, T2
ID 1074, T2
ID 1084, T0

ID 1110, T3
ID 1139, T3
ID 1159, T3
ID 1176, T1
ID 1201, T1

ID 1203, T3
ID 1206, T3
ID 1225, T2
ID 1219, T2
ID 1228, T3

 

14 exams rejected since 2008 (in Level 2b but not in 2a)

 

ID 1035, T3
ID 1045, T0
ID 1047, T0
ID 1053, T1
ID 1053, T3

ID 1055, T0
ID 1086, T0
ID 1091, T0
ID 1095, T1
ID 1173, T2

ID 1206, T0
ID 1206, T1
+2 exams for ineligible patient, :
ACRIN ID 128 (no I-SPY ID)

Data Dictionary

A data dictionary is provided. The dictionary includes descriptions of all private DICOM attributes used in the derived maps and segmentations generated by the volumetric analysis and QC evaluations. Also included are descriptions of ancillary data provided, including demographic, clinical and survival data.

Anchor
_GoBack
_GoBack